Drug Utilization Review (DUR) Committee (Emergency Telephonic)

June 17th 2015

Members Present

Robin Cooke, PharmD, CGP
Chuck Semling, PharmD
Maggi Rader, CNM
Erin Narus, PharmD (DHSS)

Members Absent

Jenny Love, MD
John Pappenheim, MD

Non-Members Present

Tolu Balogun, PharmD (Magellan)
John Bloomfield (Drug Rep)
Laura Hill (Drug Rep)
Maggie Unknown (Drug Rep)
Tina Morse (Drug Rep)
Jason Smith (Drug Rep)
Matt Keith (Geneva Woods)

Meeting started at approximately 4:10 pm; Attendance was taken

Welcome
Meeting - to discuss new information provided to the state with regard to Hep C direct acting agents

ProDUR/Clinical Topic areas

- **Review of existing Prior Authorizations, Quantity Limits, Edits**
  - Hepatitis C, Direct Acting Agents – Genotype 1
    - Proposed clarification of criteria
      - Current criteria authorizes Metavir 2-4 equivalent; Implied in this current criteria is extrahepatic manifestations which is suggestive of advancing disease but there has been some questions brought forward to the state and a need for clarification.
      - Proposed verbiage is: "Metavir Fibrosis score F2-F4 equivalent (includes extrahepatic manifestations of advancing disease)"
    - Hep C criteria was reviewed in January 2015; VieKira was selected by the state as the sole preferred first line agent in this class
      - On January 16th 2015, the Committee unanimously approved that "Viekira and Harvoni are efficaciously equivalent and the state can decide which to be made as first line".
    - Based on new information available to the state and feedback from the provider community, it will be advantageous to allow both VieKira and Harvoni to be at parity in preferred status when treating Genotype 1.
    - The state recommends that both agents (Harvoni and VieKira) be preferred agents in the treatment of Genotype 1 Hepatitis C for Alaska Medicaid.
    - State is requesting the proposed change become effective July 1

Motion was made by M. Rader and seconded by C. Semling to allow VieKira and Harvoni to both be preferred agents for the treatment of Genotype 1. Due to the absence of 2 committee members, the final vote on the recommendations will be done electronically. Draft criteria will be posted to the Alaska Medicaid Medication Prior Authorization website coincident with being sent to the DUR Committee members for

review and electronic vote. If approved by vote, the final version of the criteria will be posted to the website and will become effective July 1, 2015.

- Public comment
    - Matt Keith – Geneva woods
        - Matt Keith commented that current reimbursement on hepatitis C agents were below his reported acquisition cost and that Geneva Woods had reached out to the State to open dialogue on the issue.
        - The State acknowledged receipt of the information and will follow up with Geneva Woods regarding the topic.
- Meeting adjourned at 4:25pm